Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Phase 2

Completed

• Conditions: Myelodysplastic Syndrome

• Registration Number: NCT00044382
• Lead Sponsor: Celgene

Brief Summary

To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .

Detailed Description

Not available

Study Timeline

• Study Start: 2002-02-01
• Study First Submitted: 2002-08-27
• Study First Submitted QC: 2002-08-28
• Study First Posted: 2002-08-29
• Primary Completion: 2007-01-01
• Study Completion: 2007-01-30
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-06
• Last Update Posted: 2019-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States